Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

CALM IVF (Schaffung von Zugehörigkeiten, Lernen und Achtsamkeit für Patienten mit In-vitro-Fertilisation)

30. September 2026 aktualisiert von: University of Iowa

Schaffung von Zugehörigkeiten, Lernen und Achtsamkeit für In-vitro-Fertilisationspatienten

The investigators have designed a psychoeducational group curriculum specifically for new in vitro fertilization (IVF) patients (both male and female) to improve their treatment knowledge, to allow them to engage more in their care, to offer a support network, to improve satisfaction, and to provide them with tools to help reduce their stress and anxiety while undergoing the IVF process. The investigators plan to have four to eight infertility patients and their partners participate in a group at a time, for which they will attend three 1-1.5 hour interactive sessions that are scheduled throughout their first IVF cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques. They will do several surveys before and after the intervention for comparison, including assessment of quality of life, depression, anxiety, resilience, and a knowledge assessment. The investigators will also track the patients to see if they pursue additional treatment in the instance of a negative pregnancy test compared to patients undergoing the standard treatment. The investigators plan to recruit a control group that receives the standard of care treatment here at the University of Iowa.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Patients and their partners (if present and consenting) will be randomized in a 2:1 fashion to two different treatment arms: A) standard of care in vitro fertilization (IVF) at the investigational institution as well as participating in an additional psychoeducational group or B) standard of care IVF at the investigational institution. The intervention group will consist of three additional evening visits for 1-1.5 hours per session. The sessions will include an interactive educational component addressing usual questions and concerns of IVF patients, such as reviewing common IVF myths, and also more information regarding treatment and technologies. Each session will also include teaching of coping strategies (such as awaiting the pregnancy test, how to cope with insensitive remarks from friends and family) as well as relaxation exercises, such as progressive muscle relaxation and deep breathing.

The patients will be consented at their new IVF visit and will take their initial assessments (FertiQoL, GAD-7, PHQ-9, the Connor-Davidson Resilience Scale, and a knowledge assessment) within 24 hours of the new visit. The patients will be assigned into groups based on when they are going through their IVF stimulations, so they will have similar experiences at similar times. Patients will take their final assessments on the third day after egg retrieval, regardless of group assignment.

When partners are present and consent to the study, they will be treated as a dyad with the patient undergoing oocyte retrieval. Some patients go through treatment alone (i.e. single adults desiring pregnancy) and therefore may not have a partner available to participate. Partners level of involvement in a cycle may very, as may their desire to participate in a psychosocial intervention. As patients and their partners make joint decisions throughout their IVF cycle and the cycle itself has a single outcome, we enrolled partners as dyads with patients when partners were present, but did not require a partner to enroll a patient.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

117

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa Hospitals and Clinics

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 99 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • All patients starting their first in vitro fertilization cycle at the University of Iowa Hospitals and Clinics

Exclusion Criteria:

  • Patients who have already undergone in vitro fertilization treatment at any institution
  • Non-English speakers
  • Fertility preservation patients
  • Patients using donor oocytes, embryos, or sperm
  • Patients taking psychotropic medications for depression or anxiety that have had a dosing adjustment within 3 months of study enrollment

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Intervention

Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.

The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.

Sonstiges: Control

Standard of care in vitro fertilization patients at our institution.

Patients will receive the standard of care IVF treatment at the University of Iowa.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in female fertility patient quality of life score during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

FertiQoL International (Fertility Quality of Life Questionnaire 2008), scored scale from 0-100, with higher values indicating a higher quality of life and low scores indicating a lower quality of life.

From enrollment to 2-4 days after oocyte retrieval

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in female GAD-7 score during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Generalized Anxiety Disorder 7-item scale, with higher scores indicating higher likelihood of an anxiety disorder and lower scores indicating less likelihood of an anxiety disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in female PHQ-9 score during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Patient Health Questionnaire, with higher score indicating increased likelihood of a depressive disorder and lower scores indicating less likelihood of a depressive disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in female Connor-Davidson Resilience Scale during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Connor-Davidson Resilience Scale, with higher scores indicating greater resilience, and lower scores indicating lower resilience

From enrollment to 2-4 days after oocyte retrieval
Change in female knowledge assessment during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Assessment of knowledge regarding IVF treatment, with higher scores indicating a greater knowledge of IVF treatment, and lower scores indicating less knowledge regarding IVF treatment

From enrollment to 2-4 days after oocyte retrieval
Likelihood of continued IVF treatment in the instance of a negative pregnancy test
Zeitfenster: Three months after embryo transfer

Patients who are not pregnant after embryo transfer will be followed for three months to assess likelihood to return for additional treatment after negative embryo transfer outcome.

Three months after embryo transfer
Change in male fertility patient quality of life score during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

FertiQoL International (Fertility Quality of Life Questionnaire 2008), scored scale from 0-100, with higher values indicating a higher quality of life and low scores indicating a lower quality of life.

From enrollment to 2-4 days after oocyte retrieval
Change in male GAD-7 score during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Generalized Anxiety Disorder 7-item scale, with higher scores indicating higher likelihood of an anxiety disorder and lower scores indicating less likelihood of an anxiety disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in male PHQ-9 score during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Patient Health Questionnaire, with higher score indicating increased likelihood of a depressive disorder and lower scores indicating less likelihood of a depressive disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in male Connor-Davidson Resilience Scale during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Connor-Davidson Resilience Scale, with higher scores indicating greater resilience, and lower scores indicating lower resilience

From enrollment to 2-4 days after oocyte retrieval
Change in male knowledge assessment during IVF treatment cycle
Zeitfenster: From enrollment to 2-4 days after oocyte retrieval

Assessment of knowledge regarding IVF treatment, with higher scores indicating a greater knowledge of IVF treatment, and lower scores indicating less knowledge regarding IVF treatment

From enrollment to 2-4 days after oocyte retrieval

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Rachel M Whynott, MD, University of Iowa

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. August 2019

Primärer Abschluss (Tatsächlich)

9. August 2021

Studienabschluss (Tatsächlich)

26. Oktober 2021

Studienanmeldedaten

Zuerst eingereicht

5. August 2019

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. August 2019

Zuerst gepostet (Tatsächlich)

7. August 2019

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 201906788

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .